WO2023107593A3 - In vivo delivery to immune cells - Google Patents

In vivo delivery to immune cells Download PDF

Info

Publication number
WO2023107593A3
WO2023107593A3 PCT/US2022/052207 US2022052207W WO2023107593A3 WO 2023107593 A3 WO2023107593 A3 WO 2023107593A3 US 2022052207 W US2022052207 W US 2022052207W WO 2023107593 A3 WO2023107593 A3 WO 2023107593A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
car
acid molecules
immune cell
delivery vehicle
Prior art date
Application number
PCT/US2022/052207
Other languages
French (fr)
Other versions
WO2023107593A2 (en
Inventor
Michael KLICHINSKY
Original Assignee
Carisma Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carisma Therapeutics Inc. filed Critical Carisma Therapeutics Inc.
Priority to AU2022407035A priority Critical patent/AU2022407035A1/en
Publication of WO2023107593A2 publication Critical patent/WO2023107593A2/en
Publication of WO2023107593A3 publication Critical patent/WO2023107593A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present disclosure provides methods of producing a modified immune cell comprising a chimeric antigen receptor (CAR), the method including the step of administering to a subject a composition comprising (a) one or more nucleic acid molecules, wherein at least a portion of the one or more nucleic acid molecules encodes the CAR, and (b) a delivery vehicle, wherein following administration of the composition one or more nucleic acid molecules are translated in an immune cell to produce a modified immune cell comprising the CAR, in the subject, and wherein the modified immune cell comprising the CAR possesses targeted effector activity. Also provided herein are compositions including (a) one or more nucleic acid molecules, wherein at least a portion of the one or more nucleic acid molecules encodes the CAR, and (b) a delivery vehicle, wherein the delivery vehicle comprises at least one targeting moiety.
PCT/US2022/052207 2021-12-09 2022-12-08 In vivo delivery to immune cells WO2023107593A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022407035A AU2022407035A1 (en) 2021-12-09 2022-12-08 In vivo delivery to immune cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163287725P 2021-12-09 2021-12-09
US63/287,725 2021-12-09

Publications (2)

Publication Number Publication Date
WO2023107593A2 WO2023107593A2 (en) 2023-06-15
WO2023107593A3 true WO2023107593A3 (en) 2023-07-27

Family

ID=86731192

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/052207 WO2023107593A2 (en) 2021-12-09 2022-12-08 In vivo delivery to immune cells

Country Status (2)

Country Link
AU (1) AU2022407035A1 (en)
WO (1) WO2023107593A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343908B (en) * 2023-12-05 2024-02-09 南京大学 CAR-T cell accurately activated by fungi, preparation method, application and pharmaceutical composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050201972A1 (en) * 2003-10-10 2005-09-15 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
WO2019209991A1 (en) * 2018-04-26 2019-10-31 Baylor College Of Medicine Immune effector cells and molecular adaptors with an antigen-cytokine complex for effective immunotherapy
US20210283179A1 (en) * 2020-03-11 2021-09-16 The Trustees Of The University Of Pennsylvania Methods and composition for gene delivery using an engineered viral particle
WO2021189059A2 (en) * 2020-03-20 2021-09-23 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021263152A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. mRNA TRANSFECTION OF IMMUNE CELLS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050201972A1 (en) * 2003-10-10 2005-09-15 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
WO2019209991A1 (en) * 2018-04-26 2019-10-31 Baylor College Of Medicine Immune effector cells and molecular adaptors with an antigen-cytokine complex for effective immunotherapy
US20210283179A1 (en) * 2020-03-11 2021-09-16 The Trustees Of The University Of Pennsylvania Methods and composition for gene delivery using an engineered viral particle
WO2021189059A2 (en) * 2020-03-20 2021-09-23 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021263152A1 (en) * 2020-06-26 2021-12-30 Carisma Therapeutics Inc. mRNA TRANSFECTION OF IMMUNE CELLS

Also Published As

Publication number Publication date
AU2022407035A1 (en) 2024-05-23
WO2023107593A2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
AU2017312113B2 (en) Nucleic acid products and methods of administration thereof
TWI820027B (en) Compositions and methods for internalizing enzymes
EP3134131B1 (en) Nucleic acid vaccines
AU2016218977B2 (en) Nucleic acid products and methods of administration thereof
EP3290440A1 (en) Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof
WO2023107593A3 (en) In vivo delivery to immune cells
KR20220100078A (en) Methods and products for nucleic acid production and delivery
BRPI0510271A (en) Ex vivo applications microparticulate therapeutic agents
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
BR112013030432A2 (en) method for preparing a target conjugate peptide for a recombinant lysosomal enzyme, method for preparing a molecule for enzyme replacement therapy, conjugate, method for treating an individual suffering from a lysosomal storage disease, method for treating an individual suffering from a lysosomal storage, method for treating a patient suffering from pompe disease, fabry disease, and gaucher disease, mps i, mps ii, tay sachs, sandhoff, alpha-mannosidosis, and wohlman, dna sequence, and sequence of amino acids
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
WO2011094671A3 (en) N-terminally conjugated polypeptides for targeted therapy and diagnosis
CA3132188A1 (en) Compositions and methods for the prevention and/or treatment of covid-19
WO2023102550A3 (en) Compositions and methods for efficient in vivo delivery
MX2022008412A (en) Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy.
CN115175704A (en) Interleukin 10 conjugates and uses thereof
US11203755B2 (en) Chemically-modified siRNA
WO2022095853A1 (en) Preparation for and application of lysosome-targeting nucleic acid chimera
Asai et al. An interaction between S• tag and S• protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery
WO2024077232A3 (en) Compositions and methods for t cell targeted delivery of therapeutic agents and activation of t cells
Ma et al. Advances in research based on antibody-cell conjugation
WO2023154904A3 (en) Compositions and methods for treating acute myeloid leukemia
WO2023117378A1 (en) Engineered extracellular vesicles with improved cargo delivery
WO2023015205A3 (en) Compositions and methods for improved gene editing
WO2008146841A1 (en) Nucleic acid carrier for introduction of nucleic acid into cancer cell

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22905102

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022407035

Country of ref document: AU

Date of ref document: 20221208

Kind code of ref document: A